Human trials of coronavirus vaccine developed by scientists at the Oxford University have proven to be successful, the University has announced. According to the University, if approved by the regulators, the vaccine will be available to the UK as early as possible.
The University has in the meantime agreed to a deal with pharmaceutical giants AstraZeneca to mass-produce the vaccine which is known as ChAdOx1 nCoV-19. Details of the agreement – described by Health Secretary Matt Hancock as ‘hugely welcome news’ – are set to be finalised in the coming weeks.
Speaking on BBC Radio 4’s Today programme, Professor Sir John Bell, of Oxford University, said he hoped that some results from a human trial of the vaccine would be available by the middle of June.
Sir John added: ‘We also want to make sure that the rest of the world will be ready to make this vaccine at scale so that it gets to populations in developing countries, for example, where the need is very great.
Both partners have agreed to operate on a not-for-profit basis for the duration of the pandemic, the university said, with only the costs of production and distribution being covered.
In a separate promising development, major drug giant Pfizer yesterday announced it may have a coronavirus vaccine ready by the autumn. The US-based company has already started mass manufacturing doses and is aiming to have ‘hundreds of millions of doses’ ready by the end of the year.